JP2018522823A5 - - Google Patents

Download PDF

Info

Publication number
JP2018522823A5
JP2018522823A5 JP2017560655A JP2017560655A JP2018522823A5 JP 2018522823 A5 JP2018522823 A5 JP 2018522823A5 JP 2017560655 A JP2017560655 A JP 2017560655A JP 2017560655 A JP2017560655 A JP 2017560655A JP 2018522823 A5 JP2018522823 A5 JP 2018522823A5
Authority
JP
Japan
Prior art keywords
unsubstituted
substituted
carboxamide
piperidin
phenylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017560655A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018522823A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/035489 external-priority patent/WO2016196776A2/en
Publication of JP2018522823A publication Critical patent/JP2018522823A/ja
Publication of JP2018522823A5 publication Critical patent/JP2018522823A5/ja
Pending legal-status Critical Current

Links

JP2017560655A 2015-06-02 2016-06-02 ブルトン型チロシンキナーゼの阻害剤 Pending JP2018522823A (ja)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201562169941P 2015-06-02 2015-06-02
US201562169935P 2015-06-02 2015-06-02
US201562169945P 2015-06-02 2015-06-02
US62/169,935 2015-06-02
US62/169,941 2015-06-02
US62/169,945 2015-06-02
US201562249340P 2015-11-01 2015-11-01
US201562249336P 2015-11-01 2015-11-01
US201562249338P 2015-11-01 2015-11-01
US62/249,338 2015-11-01
US62/249,340 2015-11-01
US62/249,336 2015-11-01
PCT/US2016/035489 WO2016196776A2 (en) 2015-06-02 2016-06-02 Inhibitors of bruton's tyrosine kinase

Publications (2)

Publication Number Publication Date
JP2018522823A JP2018522823A (ja) 2018-08-16
JP2018522823A5 true JP2018522823A5 (OSRAM) 2019-07-04

Family

ID=57441893

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017560655A Pending JP2018522823A (ja) 2015-06-02 2016-06-02 ブルトン型チロシンキナーゼの阻害剤

Country Status (14)

Country Link
US (2) US20180305348A1 (OSRAM)
EP (1) EP3310776A4 (OSRAM)
JP (1) JP2018522823A (OSRAM)
KR (1) KR20180021740A (OSRAM)
CN (1) CN107709315A (OSRAM)
AU (2) AU2016270907B2 (OSRAM)
BR (1) BR112017025986A2 (OSRAM)
CA (1) CA2987054A1 (OSRAM)
IL (1) IL255831A (OSRAM)
MA (1) MA42623A (OSRAM)
MX (1) MX2017015574A (OSRAM)
RU (1) RU2017145650A (OSRAM)
SG (1) SG10201911523YA (OSRAM)
WO (1) WO2016196776A2 (OSRAM)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017383236B2 (en) * 2016-12-21 2022-02-10 Acerta Pharma B.V. Imidazopyrazine inhibitors of Bruton's tyrosine kinase
KR101956815B1 (ko) * 2017-02-14 2019-03-12 한국화학연구원 트리아졸로피리다진 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 브루톤티로신 키나제 활성 관련 질환의 예방 또는 치료용 약학적 조성물
CN109384774B (zh) * 2017-08-11 2023-02-17 中国科学院上海药物研究所 一类多取代的吡嗪/三嗪酰胺类化合物及其制备方法和应用
CN108530450B (zh) * 2018-05-03 2021-03-30 赖建智 具有egfr抑制活性的化合物、制备方法及其在疾病治疗中的应用
CN112469414A (zh) 2018-05-25 2021-03-09 昂科库博疗法有限责任公司 作为新型候选抗癌药物的高效力tacc3抑制剂
BR122023024103A2 (pt) 2018-10-15 2024-02-20 Nurix Therapeutics, Inc. Compostos bifuncionais para degradação de btk por meio da via de proteossoma de ubiquitina, composição farmacêutica compreendendo os mesmos, e seus usos
FI3870579T3 (fi) * 2018-10-22 2025-01-02 Alumis Inc Tyk2-inhibiittoreita ja niiden käyttöjä
US20220143195A1 (en) * 2019-02-13 2022-05-12 Nurix Therapeutics, Inc. Bifunctional compounds for degrading btk via ubiquitin proteosome pathway
JP2022526713A (ja) 2019-03-21 2022-05-26 オンクセオ がんの処置のための、キナーゼ阻害剤と組み合わせたDbait分子
WO2020210508A1 (en) 2019-04-09 2020-10-15 Nurix Therapeutics, Inc. 3-substituted piperidine compounds for cbl-b inhibition, and use of a cbl-b inhibitor in combination with a cancer vaccine and/or oncolytic virus
US11530229B2 (en) 2019-05-17 2022-12-20 Nurix Therapeutics, Inc. Cyano cyclobutyl compounds for CBL-B inhibition and uses thereof
US11401267B2 (en) 2019-06-26 2022-08-02 Nurix Therapeutics, Inc. Substituted benzyl-triazole compounds for Cbl-b inhibition, and further uses thereof
US20210085717A1 (en) 2019-09-24 2021-03-25 Nurix Therapeutics, Inc. Cbl inhibitors and compositions for expansion of immune cells
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021113557A1 (en) 2019-12-04 2021-06-10 Nurix Therapeutics, Inc. Bifunctional compounds for degrading btk via ubiquitin proteosome pathway
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
EP4159731A4 (en) * 2020-06-01 2024-06-26 Wigen Biomedicine Technology (Shanghai) Co., Ltd. New pyrazine compound
WO2022071772A1 (ko) * 2020-09-29 2022-04-07 (주)메디톡스 단백질 키나제 저해제 및 그의 용도
US12016860B2 (en) 2021-04-08 2024-06-25 Nurix Therapeutics, Inc. Combination therapies with Cbl-b inhibitor compounds
WO2022221194A1 (en) * 2021-04-12 2022-10-20 A2A Pharmaceuticals, Inc. Compositions and methods for treating cancer
IL309427A (en) * 2021-07-01 2024-02-01 Hangzhou Healzen Therapeutics Co Ltd TYROSINE KINASE AND MUTANT DEGRADER, Broughton's composition and application
CA3236073A1 (en) 2021-10-26 2023-05-04 Robert J. Brown Piperidinylpyrazine-carboxamide compounds for treating and preventing cancer and for degrading btk
CN116143757B (zh) * 2021-11-22 2024-07-05 杭州和正医药有限公司 一种可降解btk激酶的多功能化合物、组合物及应用
EP4499625A1 (en) 2022-03-24 2025-02-05 A2A Pharmaceuticals, Inc. Compositions and methods for treating cancer

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000075113A1 (en) * 1999-06-09 2000-12-14 Yamanouchi Pharmaceutical Co., Ltd. Novel heterocyclic carboxamide derivatives
JP4622047B2 (ja) * 1999-06-09 2011-02-02 アステラス製薬株式会社 新規なヘテロ環カルボキサミド誘導体
JP2014005206A (ja) * 2010-10-22 2014-01-16 Astellas Pharma Inc アリールアミノヘテロ環カルボキサミド化合物
JP5878178B2 (ja) * 2011-09-30 2016-03-08 大鵬薬品工業株式会社 1,2,4−トリアジン−6−カルボキサミド誘導体
US9216173B2 (en) * 2011-10-05 2015-12-22 Merck Sharp & Dohme Corp. 2-Pyridyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors
SG10201601352UA (en) * 2011-11-23 2016-03-30 Portola Pharm Inc Pyrazine kinase inhibitors
EP2802567B1 (en) * 2012-01-10 2017-03-01 F. Hoffmann-La Roche AG Pyridazine amide compounds and their use as syk inhibitors
ME02648B (me) * 2012-01-17 2017-06-20 Astellas Pharma Inc Jedinjenje pirazin karboksamida
US20140113931A1 (en) * 2012-06-22 2014-04-24 Portola Pharmaceuticals, Inc. Substituted picolinamide kinase inhibitors
US9040530B2 (en) * 2012-06-22 2015-05-26 Portola Pharmaceuticals, Inc. 1,2,4-triazine-6-carboxamide kinase inhibitors
HK1217695A1 (zh) * 2013-03-05 2017-01-20 F. Hoffmann-La Roche Ag 布鲁顿氏酪氨酸激酶抑制剂
WO2014153280A1 (en) * 2013-03-22 2014-09-25 Merck Sharp & Dohme Corp. 2-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors
WO2015039613A1 (zh) * 2013-09-18 2015-03-26 北京韩美药品有限公司 抑制btk和/或jak3激酶活性的化合物
KR20160093675A (ko) * 2013-12-05 2016-08-08 파마싸이클릭스 엘엘씨 브루톤 티로신 키나제의 억제제

Similar Documents

Publication Publication Date Title
JP2018522823A5 (OSRAM)
RU2017145650A (ru) Ингибиторы тирозинкиназы брутона
JP2015517981A5 (OSRAM)
CN103221047B (zh) 化合物和方法
JP2015524837A5 (OSRAM)
RU2010101633A (ru) Новое сульфонамидное производное малоновой кислоты и его фармацевтическое применение
JP2013545791A5 (OSRAM)
JP2015529224A5 (OSRAM)
JP2013517278A5 (OSRAM)
JP2010538076A5 (OSRAM)
JP2014508128A5 (OSRAM)
JP2012236838A5 (OSRAM)
JP2017533968A5 (OSRAM)
JP2017530199A5 (OSRAM)
SI2509955T1 (en) Pyrazole derivatives as calcium channel modulators activated by the release of calcium
JP2014505037A5 (OSRAM)
HRP20251220T1 (hr) Derivati bipirazola kao jak inhibitori
RU2009126624A (ru) Производные 2-(пиперидин-4-ил)-4-фенокси-или фенилаинопиримидина в качестве ненуклеозидных ингибитров обратной транскриптазы
JP2012525336A5 (OSRAM)
JP2010540462A5 (OSRAM)
JP2017511357A5 (OSRAM)
JP2016501250A5 (OSRAM)
JP2006500369A5 (OSRAM)
CA2422342A1 (en) Novel amide derivatives and medicinal use thereof
JP2018048143A5 (OSRAM)